|
A Vancouver-based drug repurposing company will conduct human trials on patients with acute lung injury in the U.S. and Canada.
Chris Moreau, CEO of Algernon Pharmaceuticals Inc., said the U.S. Food and Drug Administration approved the company’s application on June 3 for a human study of its repurposed drug Ifenprodil as a potential therapeutic treatment for patients with COVID-19.
|